Drug news
Teva suspends sales of Zecuity (sumatriptan iontophoretic transdermal system) in US.
Teva Pharmaceutical Industries, Ltd.announced hat it will voluntarily suspend sales, marketing and distribution of Zecuity (sumatriptan iontophoretic transdermal system). Teva has received post-marketing reports of application site reactions described as burns and scars in patients treated with Zecuity, and is working in full cooperation with the FDA to better understand these adverse events. In addition to this voluntary suspension, Teva has initiated a pharmacy-level recall of the product.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins